Metabolically active brown adipose tissue in PPGL: an observational cohort study
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0200 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Eduard Oštarijaš und 14 weiteren Autor:innen. Hauptthemen laut MEDLINE: Adipose Tissue, Brown, Adrenal Gland Neoplasms, Pheochromocytoma, Paraganglioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Brown adipose tissue (BAT) activity, identifiable through fluorodeoxyglucose positron emission tomography (FDG-PET), has gained interest due to its potential link with metabolic disorders and tumour pathophysiology. This study aims to explore the activation of BAT in patients with phaeochromocytoma/paraganglioma (PPGL) and its clinical relevance. This retrospective observational study, conducted in a large academic centre in London, reviewed FDG-PET images of 62 confirmed PPGL patients, collected between 2013 and 2021. We assessed patient demographics, biochemistry, radiological features, mutational status and outcomes, focussing on activated BAT detection. Of the 62 patients, 13% demonstrated active brown adipose tissue (aBAT) on FDG-PET imaging. Histopathological confirmation of BAT from one patient was used to validate BAT activation observed during imaging. Multivariate analysis indicated that elevated plasma normetanephrine concentrations were directly proportional to aBAT presence, suggesting their strong association with BAT activation. Despite identifying aBAT, no significant differences were found in BMI, sex, age or mutational status between aBAT-positive and aBAT-negative groups. Kaplan–Meier survival plots assessing overall and progression-free survival did not reach statistical significance. This study underscores the complex interaction between catecholamine excess and BAT activation in patients with PPGLs. The findings suggest that aBAT activity might be an indicator of severe catecholamine excess (especially normetanephrine), potentially influencing patient outcomes. Our study adds to the limited pool of knowledge and offers novel insights into BAT activation in patients with PPGLs, highlighting its potential link with metabolic derangements and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Eduard Oštarijaš, Ashley B Grossman, Georgios K Dimitriadis
Zitieren
APA
Oštarijaš, E., Onyema, M. C., Zair, Z., Taylor, D. R., Lajeunesse-Trempe, F., Reynolds, S., Mulholland, N., Corcoran, B., Halim, M., Drakou, E. E., Grossman, A. B., Vincent, R. P., Aylwin, S. J. B., Dimitriadis, G. K., & Canecki-Varžić, S. (2025). Metabolically active brown adipose tissue in PPGL: an observational cohort study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0200
Vancouver
Oštarijaš E, Onyema MC, Zair Z, Taylor DR, Lajeunesse-Trempe F, Reynolds S, et al. Metabolically active brown adipose tissue in PPGL: an observational cohort study. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0200
BibTeX
@article{Otarija2025,
author = {Oštarijaš, Eduard and Onyema, Michael C and Zair, Zoulikha and Taylor, David R and Lajeunesse-Trempe, Fannie and Reynolds, Saira and Mulholland, Nicola and Corcoran, Ben and Halim, Mohamed and Drakou, Eftychia E and Grossman, Ashley B and Vincent, Royce P and Aylwin, Simon J B and Dimitriadis, Georgios K and Canecki-Varžić, Silvija},
title = {Metabolically active brown adipose tissue in PPGL: an observational cohort study},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0200}
}
EUVIMED